Partnership

Dr. GPCR x Celtarys Reseach

Empowering medicinal biochemists

Celtarys empowers medicinal biochemists by providing innovative fluorescent probes that de-risk the pre-clinical drug discovery phase. Our proprietary conjugation technology and unparalleled scientific expertise ensure researchers can confidently advance their projects with greater precision and reliability.

Visit Website

About Celtarys Research

Celtarys Research develops and commercializes new chemical tools to spread the use of fluorescence-based methods in the pre-clinical phase of drug discovery. Our proprietary chemical conjugation technology allows us to grow, in a competitive manner and in a short time (<3 months), customized fluorescent ligands with optimal pharmacological and photophysical properties for any druggable target.

We have a catalogue of over 30 fluorescent ligands for different families of GPCRs, including adenosine, dopamine, serotonin, cannabinoid and muscarinic receptors. We also offer our expertise in the form of custom development services, where we tackle challenging targets and synthesize probes with the most suitable properties for your needs.

Meet the Celtarys Team

Wilson Gomes

CEO

Wilson Gomes holds a Mechanical Engineering degree, an MBA from the University of North Carolina, and completed the General Management Program at Harvard Business School. He has over 20 years of experience in the medtech and diagnostics industries, having held senior roles at Johnson & Johnson and Danaher across the EMEA region in sales, marketing, and general management.

He joined Celtarys as CEO in 2024, where he is responsible for driving strategy and growth. His focus is on expanding commercial reach and accelerating the adoption of the company’s GPCR assay technologies.

Maria Majellaro

Co-Funder and CSO

Dr. Maria Majellaro earned her degree in Pharmaceutical Chemistry and Technology from the University of Bari and completed her PhD in Biomolecular Sciences in Pharmacology and Medicine as “Doctor Europeus” in 2018. She then joined the University of Santiago de Compostela as a postdoctoral researcher in Prof. Eddy Sotelo’s group, contributing to the IGNICIA tech transfer project and the validation of Celtarys’ core technology.

In 2021, she co-founded Celtarys and now leads the company’s scientific direction. Her work focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools for pharma, biotech, and academic partners.

Podcast Episode

Baking Molecules, Building Probes: When Chemists Think Like Biologists

Episode #168 • Dr. GPCR Talks with Dr. Maria Majellaro

"We always start with the problem, then generate the right compound using our chemistry. It’s about enabling biology.”

Celtarys News & Updates

Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies

Choosing the right fluorescent tools is important for the success of drug discovery, just as much as choosing the right targets. One of the best tools to study therapeutic targets are fluorescent ligands, which are very useful in GPCR drug discovery, starting from hit and lead validation all the way to pre-clinical assays. Some of the advantages of using fluorescent ligands for this are

Lucía from Celtarys Research

Sep 234 min read

Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research

What is Homogeneous Time-Resolved Fluorescence (HTRF)? HTRF is a hybrid detection technology that combines Förster Resonance Energy...

Lucía from Celtarys Research

Sep 174 min read

2 3 4 5

Our Partnership

Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools

Boston, MA and Santiago de Compostela, Spain — June 3rd, 2025 — Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, is proud to welcome Celtarys Research to its partner ecosystem.

This collaboration aims to amplify the visibility and adoption of Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics.

Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology tools to support real-time, non-radioactive GPCR assays. These tools enable high-resolution binding studies, kinetic analysis, and live-cell imaging, empowering both academic and industrial scientists to uncover GPCR biology with greater precision and speed.

“We’re thrilled to partner with Celtarys and introduce their high-performance fluorescent ligands to our global GPCR community,” said Dr. Yamina Berchiche, Founder and CEO of Dr. GPCR. “These tools can dramatically improve how scientists measure ligand-receptor interactions, visualize binding in live cells, and design better experiments, core to advancing GPCR-targeted discovery.”

“Dr. GPCR provides a unique platform to reach scientists at every stage of GPCR research,” said Wilson Gomes, CEO of Celtarys Research. “This partnership will help accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic breakthroughs.”

“We’re excited to support the GPCR community with tools that deliver clarity, sensitivity, and speed,” added Dr. Maria Majellaro, CSO of Celtarys. “Working with Dr. GPCR allows us to engage with researchers worldwide who are shaping the future of receptor-targeted therapies.”

To explore Celtarys Research’s catalog and learn more about their GPCR tools, visit https://www.ecosystem.drgpcr.com/celtarys-research